FDA assigned a four-letter nonproprietary name suffix to Genentech's Hemlibra because an expedited review left little time to evaluate the sponsor's late-submitted proposals; UltraGenyx asked FDA to assign one for Mepsevii, while Spark submitted 10 suffix candidates for Luxturna only to see all of them rejected for being too meaningful.
The first three novel biologics to receive US FDA approval with distinguishable nonproprietary name suffixes had their four-letter qualifiers generated by the agency, not the product sponsors.
One year after FDA's final guidance on biologic product nonproprietary naming came out, the agency's approach to requesting, generating and...